Japanese firms sign new TB alliances
This article was originally published in Scrip
Executive Summary
Two major Japanese pharmaceutical companies have separately announced new research collaborations aimed at tuberculosis, with Dainippon Sumitomo Pharma (DSP) entering a new vaccine consortium and Eisai to work on small molecules with a leading academic institute in the US.